loading page

Comparison of Porcine Versus Bovine Surfactant in preterm respiratory distress syndrome: Evidence from real world data. A multicenter collaboration from Karnataka
  • +9
  • Abhishek Aradhya ,
  • Sharath Ghalige S,
  • Babu Madarkar,
  • Pruthvishree HV,
  • Praveen Venkatagiri,
  • Prashant Urs,
  • Daizy Ngangom,
  • Sandeep Rangaiah,
  • Vimal Kumar,
  • Chinnaraja Harini,
  • Arpna Bansal,
  • Maneesha Halkar P
Abhishek Aradhya
Ovum Hospitals

Corresponding Author:[email protected]

Author Profile
Sharath Ghalige S
Ovum Hospitals
Author Profile
Babu Madarkar
Rainbow Children's Hospital and BirthRight by Rainbow Marathahalli
Author Profile
Pruthvishree HV
Ovum Woman & Child Speciality Hospital Banaswadi
Author Profile
Praveen Venkatagiri
Chinmaya Mission Hospital
Author Profile
Prashant Urs
Apollo Hospitals Bannerghatta
Author Profile
Daizy Ngangom
Rainbow Children's Hospital and BirthRight by Rainbow Marathahalli
Author Profile
Sandeep Rangaiah
Ovum Hospitals
Author Profile
Vimal Kumar
Ovum Woman & Child Speciality Hospital Banaswadi
Author Profile
Chinnaraja Harini
Chinmaya Mission Hospital
Author Profile
Arpna Bansal
Apollo Hospitals Bannerghatta
Author Profile
Maneesha Halkar P
Ovum Hospitals
Author Profile

Abstract

BACKGROUND & OBJECTIVES: Porcine surfactant (200 mg/kg initial dose) seems to be superior over bovine surfactants (100 mg/kg) in respiratory distress syndrome (RDS). There is limited data on choice of surfactant from the developing world. Logically using higher doses of porcine surfactant comes with additional burden of cost. We decided to evaluate the clinical effect of different types of surfactants. METHODS: A retrospective analysis was conducted from August 2019 to December 2022 in 6 tertiary centres. Neonates 24-34 weeks of gestation with RDS requiring either porcine (200 mg/kg) or bovine surfactant (100 mg/kg) were enrolled. The proportion of combined outcomes of death and or CLD, redosing and other morbidities in either group were analysed. The subgroup of preterm >28 weeks and outcomes between different surfactants were analysed. RESULTS: Out of 1149 eligible babies, 302 (26%) received surfactant after stabilisation with CPAP. 158 received porcine and 144 received bovine surfactant via INSURE technique. There was a higher combined outcome of death or CLD in porcine compared to the bovine group [48 (30%) vs 20 (13%), OR:2.7; 95% CI:1.5-4.8; p=0.001] and similar combined outcomes in >28 weeks sub-group. Redosing [27 (17%) Vs 18 (12%), OR:1.4; 95% CI:0.7-2.7; p=0.2] was similar. Other morbidities like air leak, invasive ventilation, CPAP duration were similar between both the groups and different types of surfactants. CONCLUSION: Porcine surfactant at 200mg/kg had similar combined outcomes of death/ CLD and redosing compared to bovine surfactant in preterm >28 weeks. Considering the cost burden in the developing world, the efficacy needs evaluation in randomised clinical trials.
12 Jun 2023Submitted to Pediatric Pulmonology
12 Jun 2023Submission Checks Completed
12 Jun 2023Assigned to Editor
12 Jun 2023Review(s) Completed, Editorial Evaluation Pending
14 Jun 2023Reviewer(s) Assigned
19 Jul 2023Editorial Decision: Revise Major
02 Oct 20231st Revision Received
06 Oct 2023Submission Checks Completed
06 Oct 2023Assigned to Editor
06 Oct 2023Reviewer(s) Assigned
06 Oct 2023Review(s) Completed, Editorial Evaluation Pending
07 Nov 2023Editorial Decision: Revise Minor